BIND Biosciences announced that it has initiated a Phase I clinical trial to assess the safety, tolerability and pharmacokinetic profile of BIND-014 in cancer patients.

BIND-014 is the first product candidate to enter clinical evaluation from BIND’s broad proprietary Medicinal Nanoengineering platform, is a targeted polymeric nanoparticle containing the cytotoxic agent, docetaxel.  The Phase I study has an ascending, intravenous dose design to assess the safety, tolerability and pharmacokinetics of BIND-014 in approximately 30 cancer patients. The primary objective of the study is to determine the maximum tolerated dose of BIND-014 and to assess preliminary evidence of antitumor activity.  Patients are currently being screened for eligibility in this clinical trial, which is being conducted at the Virginia G. Piper Cancer Center at Scottsdale Healthcare in Scottsdale, Arizona in collaboration with the Translational Genomics Research Institute (TGen) and the Scottsdale Healthcare Research Institute.

Source:

BIND Biosciences, Inc.